EUVIMEDEUVIMED entdecken
Crossref

Reduction of Pre-Existing Adaptive Immune Responses Against SaCas9 in Humans Using Epitope Mapping and Identification

Xiaoting Shen, Qinru Lin, Zhiming Liang, Jing Wang, Xinyi Yang, Yue Liang, Huitong Liang, Hanyu Pan, Jinlong Yang, Yuqi Zhu, Min Li, Weirong Xiang und 1 weitere

The CRISPR Journal · 01.06.2022 · 5 (3) · 445-456

DOI: 10.1089/crispr.2021.0142 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The CRISPR Journal, online erschienen am 08.06.2022. Verfasst von Xiaoting Shen und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School …. Hauptthemen laut MEDLINE: Gene Editing, Staphylococcus aureus. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The CRISPR-Cas9 system is increasingly being used as a gene editing therapeutic technique in complex diseases but concerns remain regarding the clinical risks of Cas9 immunogenicity. In this study, we detected antibodies against Staphylococcus aureus Cas9 (SaCas9) and anti-SaCas9 T cells in 4.8% and 70% of Chinese donors, respectively. We predicted 135 SaCas9-derived B cell epitopes and 50 SaCas9-derived CD8+ T cell epitopes for HLA-A*24:02, HLA-A*11:01, and HLA-A*02:01. We identified R338 as an immunodominant SaCas9 B cell epitope and SaCas9_200–208 as an immunodominant CD8+ T cell epitope for the three human leukocyte antigen allotypes through immunological assays using sera positive for SaCas9-specific antibodies and peripheral blood mononuclear cells positive for SaCas9-reactive T cells, respectively. We also demonstrated that an SaCas9 variant bearing an R338G substitution reduces B cell immunogenicity and retains its gene-editing function. Our study highlights the immunological risks of the CRISPR-Cas9 system and provides a solution to mitigate pre-existing adaptive immune responses against Cas9 in humans.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gene EditingStaphylococcus aureusCRISPR-Cas SystemsEpitope MappingHLA-A AntigensHumansImmunityLeukocytes, Mononuclear

Substanzen

HLA-A Antigens

Autor:innen und Institutionen

  • State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai, China.

ORCID-Profile: Huanzhang Zhu

Zitieren

APA

Shen, X., Lin, Q., Liang, Z., Wang, J., Yang, X., Liang, Y., Liang, H., Pan, H., Yang, J., Zhu, Y., Li, M., Xiang, W., & Zhu, H. (2022). Reduction of Pre-Existing Adaptive Immune Responses Against SaCas9 in Humans Using Epitope Mapping and Identification. The CRISPR Journal, 5(3), 445-456. https://doi.org/10.1089/crispr.2021.0142

Vancouver

Shen X, Lin Q, Liang Z, Wang J, Yang X, Liang Y, et al. Reduction of Pre-Existing Adaptive Immune Responses Against SaCas9 in Humans Using Epitope Mapping and Identification. The CRISPR Journal. 2022;5(3):445-456. doi:10.1089/crispr.2021.0142

BibTeX
@article{Shen2022,
  author = {Shen, Xiaoting and Lin, Qinru and Liang, Zhiming and Wang, Jing and Yang, Xinyi and Liang, Yue and Liang, Huitong and Pan, Hanyu and Yang, Jinlong and Zhu, Yuqi and Li, Min and Xiang, Weirong and Zhu, Huanzhang},
  title = {Reduction of Pre-Existing Adaptive Immune Responses Against SaCas9 in Humans Using Epitope Mapping and Identification},
  journal = {The CRISPR Journal},
  year = {2022},
  volume = {5},
  number = {3},
  pages = {445--456},
  doi = {10.1089/crispr.2021.0142}
}
Kostenlos starten →